HF
CNTX icon

HRT Financial’s Context Therapeutics CNTX Stock Holding History

HRT Financial’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
+104,973
New +$245K ﹤0.01% 2940
2022
Q1 		– Sell
-10,160
Closed -$27K – 3205
2021
Q4 		$27K Buy
+10,160
New +$50.6K ﹤0.01% 2916

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial's CNTX Position: Q1 2026 in Review

HRT Financial opened a new position in Context Therapeutics (CNTX) in Q1 2026: 104,973 shares worth $275K. The stake represents ﹤0.01% of the portfolio and ranks #2940 among its holdings. This is a return to the name: HRT Financial previously reported a position in CNTX as recently as Q4 2021.

HRT Financial first reported a position in CNTX in Q4 2021 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • HRT Financial held 104,973 shares of Context Therapeutics worth $275K as of Q1 2026.
  • Context Therapeutics was a new HRT Financial position in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2940 holding.
  • HRT Financial first reported a position in Context Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.